PLIANT THERAPEUTICS, INC. (PLRX)
US Markets · Healthcare · Biotechnology
$1.13
-0.88%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$78.3M
About PLIANT THERAPEUTICS, INC.
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.